{
  "id": 566658,
  "title": "Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease",
  "url": "https://urgent.news/2026/08/11/epicrispr-lands-90m-to-advance-epigenetic-editing-drug-for-rare",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-11T12:00:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/epicrispr-series-c-epigenetic-editing-fshd/827340/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}